Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
Date:2/25/2013

NANJING, China, Feb. 25, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012 on Thursday, March 7, 2013, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Thursday, March 7 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:International toll:+65.6723.9381United States toll-free:+1.866.519.4004United States toll:+1.718.354.1231China Domestic toll-free:800.819.0121 China Domestic mobile toll-free: 

400.620.8038 Hong Kong toll:+852.2475.0994Please ask to be connected to Q4 2012 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 12783585. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.855.452.5696United States toll:+1.646.254.3697 The passcode for replay participants is 12783585. The telephone replay also will be archived on the "Investor Relations" section of the company's website for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:In the United States:Jie Liu D'EliaCindy ZhengVice PresidentBrunswick GroupSimcere Pharmaceutical GroupTel: 1-212-333-3810Tel: 86-25-8556-6666*8857In Beijing:Yue YuBrunswick Group Tel: 86-10-5960-8600
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
2. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
3. Simcere Pharmaceutical Group to Announce Second Quarter 2012 Financial Results on Friday, August 10, 2012
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
5. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
6. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
8. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
9. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016 ... Molecular Imaging and its Application to Drug Development Including ... Alacrita , the life sciences consulting firm, today ... PhD, as an Associate Partner in its ... Colin G Miller, PhD, in the firm,s Medical Imaging ...
(Date:5/5/2016)... 2016  Endo International plc (NASDAQ: ... Brian Lortie , President, U.S. Branded Pharmaceuticals, has ... the appointment of a successor. Mr. Lortie joined ... business with responsibility for all strategic, commercial and ... portfolio development, commercial operations, managed markets, manufacturing, supply ...
(Date:5/5/2016)... Grand Cayman , May 5, 2016 Progra ... successful trial of Oxitec , s mosquito ... Aedes aegypti by 96 % ... (MRCU) announced a new plan to fight wild Aedes aegypti, the ... these diseases on the island of Grand Cayman .  MRCU, ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... ... scheduled to provide a unique keynote address at the 2016 Learning Summit ... stories of five community college students. Their stories—of complicated family issues, financial difficulties, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with its moderate humidity ... is too cold, dry or hot, water on the eye surface can evaporate, creating ... the surrounding air. There’s only one problem, according to radio show and water advocate ...
(Date:5/6/2016)... ... May 06, 2016 , ... From the Speaker Podium ... Technology will share its insights on managing Customers Engagement at SpeechTek 2016 Event, ... 2016, Presence Technology will deliver a Presentation on “5 Customer Engagement Strategies ...
(Date:5/6/2016)... ... May 06, 2016 , ... Expert mattress researchers and ... launching in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com . The move ... sheets, mattress toppers, bed frames, and more. , Founder and Editor-in-Chief Derek Hales ...
Breaking Medicine News(10 mins):